Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction.

S. Hirohata, S. Kusachi, M. Murakami, T. Murakami, I. Sano, T. Watanabe, I. Komatsubara, J. Kondo, T. Tsuji

First Department of Internal Medicine, Okayama University Medical School, Japan.

OBJECTIVE: To test the hypothesis that changes in serum matrix metalloproteinase-1 (MMP-1) and tissue inhibitors of metalloproteinase-1 (TIMP-1) after acute myocardial infarction reflect extracellular matrix remodelling and the infarct healing process. PATIENTS: 13 consecutive patients with their first acute myocardial infarction who underwent successful reperfusion. METHODS: Blood was sampled on the day of admission, and on days 2, 3, 4, 5, 7, 14, and 28. Serum MMP-1 and TIMP-1 were measured by one step sandwich enzyme immunoassay. Left ventricular volume indices were determined by left ventriculography performed four weeks after the infarct. RESULTS: Serum concentrations of both MMP-1 and TIMP-1 changed over time. The average serum MMP-1 was more than 1 SD below the mean control values during the initial four days, increased thereafter, reaching a peak concentration around day 14, and then returned to the middle control range. Negative correlations with left ventricular end systolic volume index and positive correlations with left ventricular ejection fraction were obtained for serum MMP-1 on day 5, when it began to rise, and for the magnitude of rise in MMP-1 on day 5 compared to admission. Serum TIMP-1 at admission was more than 1 SD below the mean control value, and increased gradually thereafter, reaching a peak on around day 14. Negative correlations with left ventricular end systolic volume index and positive correlations with left ventricular ejection fraction were obtained for serum TIMP-1 on days 5 and 7, and for the magnitude of rise in TIMP-1 on days 5 and 7 compared to admission. CONCLUSIONS: Both MMP-1 and TIMP-1 showed significant time dependent alteration after acute myocardial infarction. Thus MMP-1 and TIMP-1 may provide useful information in evaluating the healing process as it affects left ventricular remodelling after acute myocardial infarction.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Kelly, D., Khan, S. Q., Thompson, M., Cockerill, G., Ng, L. L., Samani, N., Squire, I. B. (2008). Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 29: 2116-2124 [Abstract] [Full Text]  
• Spinale, F. G. (2007). Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function. Physiol. Rev. 87: 1285-1342 [Abstract] [Full Text]  
• Hudson, M. P., Armstrong, P. W., Ruzyllo, W., Brum, J., Cusmano, L., Krzeski, P., Lyon, R., Quinones, M., Theroux, P., Sydlowski, D., Kim, H. E., Garcia, M. J., Jaber, W. A., Weaver, W. D. (2006). Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction: Results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) Trial. J Am Coll Cardiol 48: 15-20 [Abstract] [Full Text]  
• Lubos, E., Schnabel, R., Rupprecht, H. J., Bickel, C., Messow, C. M., Prigge, S., Cambien, F., Tiret, L., Munzel, T., Blankenberg, S. (2006). Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J 27: 150-156 [Abstract] [Full Text]  
• Agewall, S. (2006). Matrix metalloproteinases and cardiovascular disease. Eur Heart J 27: 121-122 [Full Text]  
• Blom, A. S., Mukherjee, R., Pilla, J. J., Lowry, A. S., Yarbrough, W. M., Mingoia, J. T., Hendrick, J. W., Stroud, R. E., McLean, J. E., Affuso, J., Gorman, R. C., Gorman, J. H. III, Acker, M. A., Spinale, F. G. (2005). Cardiac Support Device Modifies Left Ventricular Geometry and Myocardial Structure After Myocardial Infarction. Circulation 112: 1274-1283 [Abstract] [Full Text]  
• Lalu, M. M., Pasini, E., Schulze, C. J., Ferrari-Vivaldi, M., Ferrari-Vivaldi, G., Bachetti, T., Schulz, R. (2005). Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 26: 27-35 [Abstract] [Full Text]  
• Nakamura, K., Hirohata, S., Murakami, T., Miyoshi, T., Demircan, K., Oohashi, T., Ogawa, H., Koten, K., Toeda, K., Kusachi, S., Ninomiya, Y., Shiratori, Y. (2004). Dynamic Induction of ADAMTS1 Gene in the Early Phase of Acute Myocardial Infarction. J Biochem 136: 439-446 [Abstract] [Full Text]  
• Sundstrom, J., Evans, J. C., Benjamin, E. J., Levy, D., Larson, M. G., Sawyer, D. B., Siwik, D. A., Colucci, W. S., Wilson, P. W.F., Vasan, R. S. (2004). Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J 25: 1509-1516 [Abstract] [Full Text]  
• Jones, C. B, Sane, D. C, Herrington, D. M (2003). Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome. Cardiovasc Res 59: 812-823 [Abstract] [Full Text]  
• Horstmann, S., Kalb, P., Koziol, J., Gardner, H., Wagner, S. (2003). Profiles of Matrix Metalloproteinases, Their Inhibitors, and Laminin in Stroke Patients: Influence of Different Therapies. Stroke 34: 2165-2170 [Abstract] [Full Text]  
• Wilson, E. M., Moainie, S. L., Baskin, J. M., Lowry, A. S., Deschamps, A. M., Mukherjee, R., Guy, T. S., St John-Sutton, M. G., Gorman, J. H. III, Edmunds, L. H. Jr, Gorman, R. C., Spinale, F. G. (2003). Region- and Type-Specific Induction of Matrix Metalloproteinases in Post-Myocardial Infarction Remodeling. Circulation 107: 2857-2863 [Abstract] [Full Text]  
• Marin, F., Roldan, V., Climent, V., Garcia, A., Marco, P., Lip, G. Y.H. (2003). Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1?. Stroke 34: 1181-1186 [Abstract] [Full Text]  
• Li, D., Williams, V., Liu, L., Chen, H., Sawamura, T., Antakli, T., Mehta, J. L. (2002). LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation. Am. J. Physiol. Heart Circ. Physiol. 283: H1795-H1801 [Abstract] [Full Text]  
• Schwartzkopff, B., Fassbach, M., Pelzer, B., Brehm, M., Strauer, B. E. (2002). Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4: 439-444 [Abstract] [Full Text]  
• Spinale, F. G. (2002). Matrix Metalloproteinases: Regulation and Dysregulation in the Failing Heart. Circ. Res. 90: 520-530 [Abstract] [Full Text]  
• Creemers, E. E.J.M., Cleutjens, J. P.M., Smits, J. F.M., Daemen, M. J.A.P. (2001). Matrix Metalloproteinase Inhibition After Myocardial Infarction: A New Approach to Prevent Heart Failure?. Circ. Res. 89: 201-210 [Abstract] [Full Text]  
• Yousef, Z R, Redwood, S R, Marber, M S (2000). Postinfarction left ventricular remodelling: where are the theories and trials leading us?. Heart 83: 76-80 [Full Text]